Mallikarjuna Nallegowda
Pain Medicine · Pueblo, CONPI 1770733743
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $843 and has fallen 56.1% since, to $370 in 2025.
Across 207 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$783
- Scilex Pharmaceuticals Inc.$682
- Boston Scientific$327
- Pfizer$270
- Collegium Pharmaceutical, Inc.$258
- Biohaven Pharmaceutical Holding Company Ltd.$188
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $783 |
| Scilex Pharmaceuticals Inc. | 46 | $682 |
| Boston Scientific | 19 | $327 |
| Pfizer | 14 | $270 |
| Collegium Pharmaceutical, Inc. | 18 | $258 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $188 |
| Amgen | 10 | $181 |
| Idorsia Pharmaceuticals US Inc | 1 | $124 |
| Supernus Pharmaceuticals, Inc. | 8 | $118 |
| Medtronic | 4 | $111 |
| Eisai Inc. | 5 | $86 |
| Avanos Medical | 1 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| AstraZeneca | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Biodelivery Sciences International, Inc. | 3 | $42 |
| Bioventus LLC | 2 | $42 |
| Pacira Therapeutics, Inc. | 2 | $41 |
| Fidia Pharma USA Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Si-bone, Inc. | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Averitas Pharma Inc. | 1 | $22 |
| Zimmer Biomet | 1 | $21 |
| USWM, LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Sebela Pharmaceuticals Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| Stimwave Technologies Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- QUVIVIQ$124
How this compares
$3,829 in reported general payments places this provider in the 60th percentile of 96 pain medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 39 | $42,183 |
| Nucynta ErTapentadol Hcl | 57 | $40,529 |
| NucyntaTapentadol Hcl | 44 | $40,001 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,213 | $34,930 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 816 | $26,046 |
| MovantikNaloxegol Oxalate | 32 | $21,968 |
| UbrelvyUbrogepant | 22 | $21,438 |
| Buprenorphine | 81 | $19,169 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $15,798 |
| Xtampza ErOxycodone Myristate | 43 | $14,580 |
| SavellaMilnacipran Hcl | 30 | $14,027 |
| Lidocaine | 139 | $12,466 |
| ZtlidoLidocaine | 21 | $12,175 |
| Celecoxib | 580 | $11,408 |
| Duloxetine Hcl | 742 | $10,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta, Xtampza Er, Belbuca | $258 | $103,612156 claims |
| PfizerNurtec Odt | $270 | $42,18339 claims |
| AbbVieUbrelvy, Savella | $783 | $35,46452 claims |
| Hikma Pharmaceuticals USABuprenorphine | $32 | $19,16981 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $682 | $12,17521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 96 pain medicine providers in Colorado.
Other pain medicine in Pueblo
- Benjamin MasseyPueblo$2K
- Robert MoghimGolden$273K
- Jack RentzGreenwood Village$264K
- Donald BernardiniEnglewood$102K
- Haley BurkeAurora$55K
- Amar PatelThornton$47K
- David ColumbusLoveland$30K
- Matthew PouliotFort Collins$26K
- Justin MerkowEnglewood$24K
- Daniel FeldmanBroomfield$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.